Latest News

FDA Greenlights Symbravo for Acute Treatment of Migraine: Daily Dose / image credit: ©New Africa/AdobeStock
FDA Greenlights Symbravo for Acute Treatment of Migraine: Daily Dose

February 6th 2025

Your daily dose of the clinical news you may have missed.

Investigators Identify Hemoglobin A1c/HDL-C as a Predictor of Stroke Risk in Older Adults
Investigators Identify Hemoglobin A1c/HDL-C as a Predictor of Stroke Risk in Older Adults

February 5th 2025

New ACP Guidelines on Prevention of Episodic Migraine Cite Lack of Comparative Evidence for Treatments  image credit  ©Parata/stock.adobe.com
New ACP Guidelines on Prevention of Episodic Migraine Cite Lack of Comparative Evidence for Treatments

February 5th 2025

FDA Approves Monthly Lecanemab for Early-Stage Alzheimer Disease: Daily Dose / image credit: ©New Africa/AdobeStock
FDA Approves Monthly Lecanemab for Early-Stage Alzheimer Disease: Daily Dose

February 4th 2025

Symbravo Mechanism of Action and Patient Selection, with PI Stewart Tepper, MD / image credit Geisel School of Medicine, Dartmouth
Symbravo Mechanism of Action and Patient Selection, with PI Stewart Tepper, MD

February 4th 2025

Video Interviews
Podcasts
Latest CME Events & Activities

Individualizing Treatment for Patients with Generalized Myasthenia Gravis

View More

A New Era in NMOSD Treatment: Optimizing Therapeutic Transitions and Reducing Patient Burden

March 1, 2025

Register Now!

Patient, Provider & Caregiver Connection™: Reducing the Burden of Parkinson Disease Psychosis with Personalized Management Plans

View More

Empowering Breast Cancer Patients with Non-Opioid Pain Management Innovations

View More

Clinical ShowCase™ in ALS: Addressing Diagnostic Delays, Evolving Therapies, and Multidisciplinary Care

View More

BURST Expert Illustrations and Commentaries™: Visualizing FcRn as a Therapeutic Target in Neurological Disease

View More

Burst Expert Illustrations & Commentary™: Visualizing the Role of FcRN in Neurological Disorders

View More

BURST Expert Illustrations and Commentaries™: Visualizing the Implications of FcRN-Targeted Therapies on Generalized Myasthenia Gravis

View More

Burst Expert Illustrations & Commentary™: Visualizing the Role of Subcutaneous Infusion as an Alternate Administration Route for Medical Interventions

View More

Clinical Consultations™: Navigating the Evolving Treatment Landscape in Generalized Myasthenia Gravis

View More

SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era

View More

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

View More

Expert Illustrations & Commentaries™: New Targets for Treatment in Cognitive Impairment in Schizophrenia – The Role of NMDA Receptors and Co-agonists

View More

BURST CME™ Part I: Understanding the Impact of Huntington’s Disease

View More

Burst CME™ Part II: The Evolving Treatment Landscape for Huntington Disease

View More

Carolina Neuromuscular Disease Summit

September 27, 2025

Register Now!

Evolving Perspectives in Alzheimer's Disease: Reaching an Earlier Diagnosis, Understanding Neuroinflammation, and Exploring Therapeutic Advances

View More

Clinical ShowCase: Developing a Personalized Treatment Plan for a Patient with Huntington’s Disease Associated Chorea

View More

SimulatEd™ From Discomfort to Relief: Acute Pain Management Essentials

View More

Medical Crossfire®: Integrating Real-World Data to Improve Outcomes for Patients With Multiple Sclerosis

View More

Medical Crossfire® - Optimizing Management for Patients With Generalized Myasthenia Gravis: Focus on Complement Inhibitors

View More

Burst CME™: The Patient Journey – Unmet Needs From Diagnosis Through Management of Migraine

View More

Burst CME™: Setting the Stage – Individualizing Migraine Care for Diverse Populations Across Care Settings

View More

Evolving Perspectives in Alzheimer Disease : Reaching an Earlier Diagnosis, Understanding Neuroinflammation, and Exploring Therapeutic Advances

View More

Burst CME™: Optimizing the Use of CGRP Targeted Agents for the Treatment of Migraine

View More

Burst CME™: Optimizing Migraine Management – Addressing Unmet Needs, Individualizing Care for Diverse Populations, and Utilizing CGRP Targeted Agents

View More

Community Practice Connections™: Optimizing the Management of Tardive Dyskinesia—Addressing the Complexity of Care With Targeted Treatment

View More

Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice

View More

Patient, Provider, and Caregiver Connection™: Pediatric Myasthenia Gravis—Current Treatment and Emerging Concepts

View More

Mind Moments™: Optimizing Management for Patients with Generalized Myasthenia Gravis

View More

More News

© 2025 MJH Life Sciences

All rights reserved.